Cited by

• Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.

  Uray IP, Brown PH. Uray IP, et al. Recent Results Cancer Res. 2011;188:147-62. doi: 10.1007/978-3-642-10858-7_13. Recent Results Cancer Res. 2011. PMID: 21253797 Free PMC article. Review.
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

  Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. Vázquez-Martín A, et al. Clin Transl Oncol. 2009 Jul;11(7):455-9. doi: 10.1007/s12094-009-0384-0. Clin Transl Oncol. 2009. PMID: 19574203 Review.
• Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity.

  Barbieri F, Verduci I, Carlini V, Zona G, Pagano A, Mazzanti M, Florio T. Barbieri F, et al. Front Oncol. 2019 Mar 13;9:135. doi: 10.3389/fonc.2019.00135. eCollection 2019. Front Oncol. 2019. PMID: 30918838 Free PMC article. Review.
• Metformin targets multiple signaling pathways in cancer.

  Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian CN, Zhang J, Lu Y. Lei Y, et al. Chin J Cancer. 2017 Jan 26;36(1):17. doi: 10.1186/s40880-017-0184-9. Chin J Cancer. 2017. PMID: 28126011 Free PMC article. Review.
• Differential crosstalk between the AMPK and PI3K/Akt pathways in breast cancer cells of differing genotypes: Leptin inhibits the effectiveness of AMPK activation.

  El-Masry OS, Al-Sakkaf K, Brown BL, Dobson PR. El-Masry OS, et al. Oncol Rep. 2015 Oct;34(4):1675-80. doi: 10.3892/or.2015.4198. Epub 2015 Aug 11. Oncol Rep. 2015. PMID: 26260992 Free PMC article.